| 72.86 0.27 (0.37%) | 06-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 89.17 | 1-year : | 104.15 |
| Resists | First : | 76.34 | Second : | 89.17 |
| Pivot price | 70.93  |
|||
| Supports | First : | 64.79 |
Second : | 57.65 |
| MAs | MA(5) : | 73.3  |
MA(20) : | 68.07 |
| MA(100) : | 67.42 |
MA(250) : | 70.72 |
|
| MACD | MACD : | 2.9 |
Signal : | 2.5 |
| %K %D | K(14,3) : | 80 |
D(3) : | 82.5 |
| RSI | RSI(14): 63.9 |
|||
| 52-week | High : | 89.98 | Low : | 54.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DXCM ] has closed below upper band by 36.2%. Bollinger Bands are 50.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 75.42 - 75.87 | 75.87 - 76.31 |
| Low: | 71.47 - 72 | 72 - 72.5 |
| Close: | 72.06 - 72.83 | 72.83 - 73.57 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Thu, 04 Jun 2026
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Thu, 04 Jun 2026
Here's Why You Should Retain DexCom Stock in Your Portfolio - The Globe and Mail
Thu, 04 Jun 2026
DexCom (DXCM) Showcases Innovations and Future Plans at ADA Scie - GuruFocus
Mon, 01 Jun 2026
Here's why you should hold DexCom stock in your portfolio for now - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 386 (M) |
| Shares Float | 384 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 102.6 (%) |
| Shares Short | 17,560 (K) |
| Shares Short P.Month | 15,190 (K) |
| EPS | 2.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.65 |
| Profit Margin | 19.3 % |
| Operating Margin | 21.4 % |
| Return on Assets (ttm) | 9.6 % |
| Return on Equity (ttm) | 35.6 % |
| Qtrly Rev. Growth | 15 % |
| Gross Profit (p.s.) | 7.67 |
| Sales Per Share | 12.49 |
| EBITDA (p.s.) | 3.34 |
| Qtrly Earnings Growth | 92.1 % |
| Operating Cash Flow | 1,780 (M) |
| Levered Free Cash Flow | 1,060 (M) |
| PE Ratio | 31.27 |
| PEG Ratio | 1.3 |
| Price to Book value | 9.51 |
| Price to Sales | 5.83 |
| Price to Cash Flow | 15.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|